ENB-824

ENB-824 is a preclinical-stage small molecule therapeutic being developed by Engine Biosciences for the treatment of solid tumors, with a specific focus on lung cancer and liver cancer. The drug was discovered using Engine's proprietary NetMAP platform, which utilizes high-throughput CRISPR screening and machine learning to identify novel synthetic lethal gene interactions and biomarkers. While the specific molecular target of ENB-824 has not been publicly disclosed, the program represents Engine's strategy of targeting genetically defined dependencies in cancer to improve treatment precision and patient outcomes.